Our robust portfolio of novel, mechanism-based therapeutics target early stages of age-related or inherited retinal disease, wherein lies the greatest opportunity to preserve vision.

*non-dilutive sources (e.g. NIH, NEI, FFB, RPB, etc.)

• SP3 formulation now entering clinical phase of development

(additional disease indications pending for SP3, SP4, SP5)

Leveraging the latest scientific breakthroughs and state-of-the-art technologies to obtain systems-level insights and identify novel, mechanism-based therapies that alleviate disease at the root cause.

Compared to traditional approaches, an inherent advantage of our systems-pharmacology platform is that it exploits integrative mechanisms of action for the treatment of complex disorders, such as AMD, in which numerous intracellular and intercellular pathways are perturbed, thereby enabling superior efficacy through global normalization of cellular and tissue homeostasis. Our innovative platform leverages the latest breakthroughs in single-cell transcriptomics and mass-spectrometry proteomics for advanced disease modeling and characterization; this approach identifies cell types and signaling pathways implicated in complex diseases, ultimately revealing novel therapeutic strategies to exploit synergistic modulation of multiple, interconnected disease processes. Additionally, this platform focuses on specific tissue(s) and disease indication(s), based on multi-omics expression profiling that identifies therapeutic targets in cells and tissues of interest, thus mitigating potential off-target side effects.

Our proprietary SRED therapies (SP3, SP4, SP5) represent a promising strategy for patients and clinicians to combat disease in earlier stages with superior efficacy over the current standard of care. 

Based on the innovative systems-pharmacology platform, we have discovered a new class of small-molecule drugs that activate intrinsic biological mechanisms of stress resilience. Given that the common thread underlying a broad spectrum of acute and chronic conditions, including every disease associated with human aging, is the impairment or loss of physiological resilience to stress, it is conceivable that our prototypical ‘stress resilience-enhancing drugs’ (SREDs) could someday be utilized by clinicians and patients to combat a wide range of disorders, including those that cause progressive, irreversible vision loss. In pre-clinical studies, we demonstrated the efficacy of our SP3, SP4, and SP5 platforms in preserving both retinal structure and function across a variety of genetic and environmental animal models of AMD, DR, RP, and glaucoma; as well as in different mammalian species. Based on this premise, we aim to introduce our SRED products to the market, initially as oral medications for the treatment or prevention of degenerative retinal diseases. SREDs will substantially bolster the arsenal of ophthalmic medications, currently limited to anti-angiogenics, corticosteroids, and nonsteroidal anti-inflammatory drugs (NSAIDs). Ultimately, SREDs hold the potential to become a mainstay therapy across a broad range of neurodegenerative disorders and clinical conditions.